

AWARD NUMBER: W81XWH-13-1-0421

TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer

PRINCIPAL INVESTIGATOR: Elizabeth Swisher, M.D.,

CONTRACTING ORGANIZATION: University of Washington
Seattle, WA 98195

REPORT DATE: October 2014

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release, distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2014	2. REPORT TYPE Annual report	3. DATES COVERED 30 Sep 2013 - 29 Sep 2014
---------------------------------------	--	--

4. TITLE AND SUBTITLE The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer	5a. CONTRACT NUMBER 5b. GRANT NUMBER W81XWH-13-1-0421 5c. PROGRAM ELEMENT NUMBER
--	--

6. AUTHOR(S) Elizabeth M. Swisher M.D. E-Mail: swishere@uw.edu	5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER
---	--

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Washington 1959 NE Pacific St Seattle, WA 98195	8. PERFORMING ORGANIZATION REPORT NUMBER
--	---

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S)
--	--

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
We have completed DNA sequencing using BROCA-HR assay developed by our group for 65 DNA repair genes using blood DNA from two clinical trials in advanced ovarian cancer, GOG 218, N=773 and GOG 262, N=573. 278 (14.7%) had mutations in *BRCA1* (182) and *BRCA2* (96). 109 (5.8%) had 112 mutations in the following genes: *BRIP1* (27), *CHEK2* (13), *RAD51D* (11), *PALB2* (11), *ATM* (11), *RAD51C* (10), *NBN* (9), *TP53* (6), *BARD1* (4), *MSH6* (4), *FAM175A* (3), *PMS2* (2), and *MLH1* (1). Consistent with their role as ovarian cancer susceptibility genes, *BRIP1*, *RAD51C*, and *RAD51D* were significantly more frequently mutated in OC than in the ESP (all $P < 0.001$). *PALB2* and *BARD1*, which are not proven ovarian cancer genes, were also significantly more frequently mutated in OC (*PALB2*: OR of 11.0, 95% CI [2.4 – 50], $p = 0.0003$; *BARD1*: OR 31, 95% CI [1.7 – 577], $p = 0.02$. *ATM*, *NBN*, *CHEK2*, and *FAM175A* mutations were not significantly more common in OC. Overall, we determined that at least 11 genes contribute to ovarian cancer and explain 20% of cases.

15. SUBJECT TERMS
Ovarian, angiogenesis, clinical trial, homologous recombination, mutation, BRCA1, BRCA2, PALB2, BARD1, RAD51C, RAD51D, BRIP1, outcomes, histology

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT 2 Unclassified	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Project summary.....	4-5
4. Accomplishments.....	5
5. Conclusions.....	5
6. Publications.....	5
7. Inventions and patents.....	5
8. Reportable outcomes.....	5
9. Other achievements.....	5
10. References.....	6
11. Appendix.....	6

INTRODUCTION:

The Gynecologic Oncology Group (GOG) trial 218 was a randomized phase III trial in primary stage III and IV ovarian carcinoma, which found a statistically significant improvement in progression free survival (PFS) for combination chemotherapy with extended bevacizumab, an antibody to the VEGF receptor that inhibits angiogenesis. However, this relatively small increase in PFS came at high financial cost and increased toxicity. Identifying biomarkers that predict increased response to bevacizumab is essential to allow more individualized and cost effective patient care. Inherited mutations in *BRCA1* and *BRCA2* (*BRCA1/2*) occur in 13-18% of all ovarian carcinomas. *BRCA1/2* are involved in the Fanconi anemia (FA) DNA repair pathway and *BRCA2* is a FA gene. Women with *BRCA1/2* mutations are known to have an improved overall survival compared to women with sporadic ovarian carcinoma. The FA-BRCA pathway controls DNA repair via homologous recombination (HR). Recently, our group and others have more broadly implicated the FA-BRCA pathway in the etiology of hereditary ovarian carcinoma, identifying a number of new ovarian cancer susceptibility genes including *BARD1*, *BRIP1*, *RAD51C*, and *RAD51D*. Our hypothesis was that women that are wildtype for germline mutations in the FA-BRCA pathway would demonstrate greater benefit from the addition of extended bevacizumab to standard induction chemotherapy for advanced ovarian carcinoma.

KEYWORDS

Ovarian cancer, angiogenesis, homologous recombination, mutation, BRCA1, BRCA2, PALB2, BARD1, RAD51C, RAD51D, BRIP1, outcomes, histology

OVERALL PROJECT SUMMARY

To date, we have achieved all projected milestones on time.

Current objectives: Our primary objective is to deeply sequence a large number of genes in the FA-BRCA pathway in germline DNA from GOG218 and correlate the presence of deleterious mutations with progression-free survival according to treatment arm. Secondly we are assessing the contribution of novel FA-BRCA genes to hereditary ovarian carcinoma including those of various histological sub-types and correlating the presence of FA-BRCA mutations with overall survival and treatment toxicity.

Summary of results, progress and accomplishments

Major activities: We have completed DNA sequencing using the BROCA-HR assay developed by our group for 65 DNA repair genes using blood DNA from GOG 218, N=773 and GOG 262, N=573. We initially planned to sequence 1200 cases from GOG 218, but germline DNA was not available from as many cases as projected. Therefore, to complete our goal to sequence germline DNA from 1200 unselected women with advanced ovarian cancer, we supplemented our GOG-218 series with 573 blood DNAs from another phase III GOG trial, GOG262. In order to achieve our stated goal for the GOG-218 treatment analyses, in year 2 we will supplement the blood DNAs already sequenced with another 500 tumor DNAs. These additional samples will allow us to evaluate both germline and somatic mutations in our target genes.

Germline mutation rates excluding copy number variations (CNVs) were compared to European American (EA) population rates from the NHLBI GO Exome Sequencing Project (ESP). ESP insertions and deletions were hand curated. Only clearly damaging mutations were included. We combined our germline mutation data from GOG218 and GOG262 with an additional 543 unselected ovarian cancer cases from the University of Washington. In total, 381/1889 (20.2%) women had 390 germline mutations in cancer-associated genes. 8/381 (2.1%) had more than one

mutation. 278 (14.7%) had mutations in *BRCA1* (182) and *BRCA2* (96). 109 (5.8%) had 112 mutations in the following genes: *BRIP1* (27), *CHEK2* (13), *RAD51D* (11), *PALB2* (11), *ATM* (11), *RAD51C* (10), *NBN* (9), *TP53* (6), *BARD1* (4), *MSH6* (4), *FAM175A* (3), *PMS2* (2), and *MLH1* (1). Consistent with their role as ovarian cancer susceptibility genes, *BRIP1*, *RAD51C*, and *RAD51D* were significantly more frequently mutated in OC than in the ESP (all $P < 0.001$). *PALB2* and *BARD1*, which were not proven ovarian cancer genes, were also significantly more frequently mutated in OC (*PALB2*: OR of 11.0, 95% CI [2.4 – 50], $p = 0.0003$; *BARD1*: OR 31, 95% CI [1.7 – 577], $p = 0.02$). *ATM*, *NBN*, *CHEK2*, and *FAM175A* mutations were not significantly more common in OC.

In GOG 218, germline *BRCA2* mutations were associated with significantly improved progression-free and overall survival ($p = 0.009$ and $p = 0.0005$, respectively). *BRCA2* carriers had more grade 4 neutropenia ($p = 0.04$). Histologic subtype, race, ethnicity, and primary site did not predict mutation status. In summary, we found that mutations in *PALB2*, *BARD1*, *BRIP1*, *RAD51C*, and *RAD51D* were more frequent in OC than in the ESP EA population.

Discussion: We have completed the sequencing of a large number of germline DNAs from two phase III ovarian cancer trials and identified two new ovarian cancer susceptibility genes, *BARD1* and *PALB2*. This brings the total of known ovarian cancer susceptibility genes to 11 and suggests that 20% of ovarian cancer is hereditary. Histology is not a significant predictor; therefore, all women with ovarian cancer should be offered genetic testing without regard to age, race, or histology.

KEY RESEARCH ACCOMPLISHMENTS

- Identified 11 hereditary ovarian cancer genes significantly more frequently mutated in women with ovarian cancer than in cancer free controls, including 2 new ovarian cancer susceptibility genes *PALB2* and *BARD1*

CONCLUSIONS

These data imply that up to 20% of ovarian cancer is preventable with widespread uptake of genetic testing and timely surgical prevention for high risk women. If achieved, more comprehensive prevention of hereditary ovarian cancer would have a significant impact on overall cancer mortality. Women in the military as well as civilian women should be assessed for familial cancer risk and referred for genetic testing when appropriate. In the next time period we will complete the sequencing of the GOG218 samples and test our primary hypothesis to determine if mutation status is a predictor of benefit from extended bevacizumab therapy.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS: Nothing to report

INVENTIONS, PATENTS AND LICENSES

Nothing to report

REPORTABLE OUTCOMES

Nothing to report

OTHER ACHIEVEMENTS

Nothing to report

REFERENCES

None

APPENDICES

None